Clostridium Infections is an indication for drug development with over 150 pipeline drugs currently active. According to GlobalData, preregistered drugs for Clostridium Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Clostridium Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Clostridium Infections overview
Clostridium infections are caused by a group of bacteria that are found in soil and can enter the body through wounds or contaminated food. These bacteria produce toxins that can damage the tissues or nerves of the infected person. Some of the diseases caused by Clostridium infections are botulism tetanus, gas gangrene, C. difficile colitis and enteritis necroticans. Clostridium infections can be serious and sometimes fatal, especially if not treated promptly. Treatment may include antibiotics, antitoxins, surgery, or supportive care. Prevention of Clostridium infections involves proper wound care, food safety, and vaccination.
For a complete picture of PTSR and LoA scores for drugs in Clostridium Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
